Turning to the companies' production growth, Sheffield said the company remains on target for 14% growth this year, expanding to 17% to 18% over the next five years. Those estimates, he noted, are with west Texas crude prices falling below $85 a barrel.
Cramer said that Pioneer remains a great growth story.
In the Lightning Round, Cramer was bullish on
Krispy Kreme Doughnuts
St Jude Medical
Cramer was bearish on
Executive Decision: Francois Nader
In his final "Executive Decision" segment, Cramer sat down with Dr. Francois Nader, president and CEO of orphan drug maker
, a stock that was crushed by 15% in today's trading.
Nader said NPS exceeded its internal expectations for the quarter and Wall Street's expectations simply got ahead of themselves. He quipped that his job is to deliver great drugs to patients and not to manage analyst expectations.
Nader also noted that for its main drug, Gattex, the addressable market still sits between 3,000 and 5,000 patients. Yet, NPS currently only has 455 prescriptions for the drug, leaving a lot of marketshare remaining. He said NPS has seen no issues with reimbursements from insurance providers for their drugs, even with their absorb anent price tags, given how much the alternatives costs.
NPS also has opportunities to expand into international markets as well as expanding their indications to include more types of patients.
Cramer said this stock's big pullback has created a great opportunity.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,